SSRIs (selective serotonin reuptake inhibitors) are generally considered safe in pregnancy by many doctors, but emerging research suggests the conversation is far more nuanced than that simple reassurance. Nearly one in five women of childbearing age takes an SSRI like Zoloft, Prozac, or Lexapro, and for many, these medications are essential for managing depression and anxiety. But when pregnancy enters the picture, the question of safety becomes urgent and complicated.

What Does the Research Actually Show About SSRIs and Birth Defects?

The evidence on SSRIs and pregnancy complications is mixed, and the inconsistencies matter. Some studies have linked paroxetine (Paxil) specifically to increased risk of certain heart defects, with a 2016 meta-analysis finding that paroxetine use during the first trimester was associated with approximately doubled risk of some cardiac malformations. However, a large 2014 U.S. study examining over 949,000 pregnancies found no statistically significant increase in overall cardiac defects after controlling for maternal factors.

The discrepancy reveals an important truth: specific SSRIs may carry different risks than others, and the absolute risk for fetal cardiac defects remains relatively small. This nuance is critical because it means blanket statements about SSRI safety miss the real picture.

When it comes to preterm birth, the story is similarly complicated. A 2016 meta-analysis found that women who received SSRIs during pregnancy had significantly higher risk of preterm birth, even after adjusting for maternal depression. But a 2024 meta-analysis found that maternal use of antidepressants in pregnancy was not associated with preterm birth when properly adjusting for maternal depression, regardless of timing. The key difference: women with more serious, treatment-resistant depression are both more likely to receive SSRIs and are independently more likely to deliver early, making it difficult to separate the medication's effect from the underlying condition.

Which Pregnancy Complications Have Clearer Evidence?

Some SSRI-related risks show more consistent patterns across studies. Approximately 25 to 30 percent of newborns exposed to SSRIs in late pregnancy show withdrawal-like symptoms after birth, including jitteriness, tremors, irritability, and difficulty breathing. The encouraging news is that these symptoms are typically mild and transient, resolving within days to weeks, with no apparent long-term consequences. However, watching a newborn experience withdrawals can be emotionally difficult for new mothers, especially those already managing anxiety.

Persistent pulmonary hypertension (PPHN), a serious lung condition, shows a more alarming pattern. A 2019 network meta-analysis found that SSRI or SNRI (serotonin-norepinephrine reuptake inhibitor) exposure during pregnancy was associated with approximately doubled risk of this condition. However, context matters: this represents approximately 2 to 3 cases per 1,000 live births compared to a background rate of about 1.2 cases per 1,000 live births. The risk doubles relatively speaking, but in absolute terms, it remains rare.

The autism question remains frustratingly unclear. Some studies have suggested associations between prenatal SSRI exposure and increased autism risk, while others have found no significant association after accounting for maternal psychiatric illness. A 2023 Kaiser Permanente study found that mothers with psychiatric conditions were more likely to have children with autism, but found no association with SSRI use itself. As with many other conditions discussed, it is difficult to say with certainty whether any neurodevelopmental risks stem from the medication or the underlying maternal mental health condition.

How to Make an Informed Decision About SSRIs and Pregnancy

• Have a detailed conversation with your doctor: Rather than accepting simple reassurance that SSRIs are "completely safe," ask your healthcare provider about the specific SSRI you take, the timing of exposure during pregnancy, and the individual risks and benefits in your particular situation.
• Understand the risks of untreated depression: Suicide is one of the leading causes of maternal death in the United States, and untreated maternal depression is associated with poor prenatal care, preterm birth, low birth weight, compromised maternal-infant bonding, higher rates of substance use, and progression to postpartum depression.
• Consider relapse rates if discontinuing: Women who discontinue antidepressants during pregnancy have markedly higher relapse rates, with one landmark study finding a 68 percent relapse rate among those who discontinued antidepressant use, compared to just 2 percent among those who continued treatment.

Dr. Adam Urato, a maternal-fetal medicine specialist with over two decades of experience caring for pregnant women in Massachusetts, has spent more than a decade challenging the medical establishment's simplified messaging around SSRIs. He has documented associations between SSRI use and preterm birth, preeclampsia, postpartum hemorrhage, and concerning effects on fetal brain development. He has co-authored large meta-analyses examining thousands of pregnancies and testified before FDA expert panels.

"Many patients report being told only that SSRIs pose no risk to the baby, which is neither accurate nor adequate," noted Dr. Adam Urato.

Dr. Adam Urato, Maternal-Fetal Medicine Specialist

Why the Risks of Untreated Mental Health Cannot Be Ignored

The complexity of the SSRI question cannot be separated from the very real dangers of untreated depression and anxiety during pregnancy. Untreated maternal depression is linked to poor prenatal care, preterm birth, low birth weight, compromised maternal-infant bonding, higher rates of substance use, and progression to postpartum depression. Additionally, suicide remains one of the leading causes of maternal death in the United States.

The stakes are high on both sides of the equation. Women who discontinue antidepressants during pregnancy face a 68 percent relapse rate, compared to just 2 percent among those who continue treatment. This means that for many women, stopping SSRIs to avoid potential pregnancy risks may actually create a different, and potentially more serious, risk to both mother and baby.

The bottom line is that there is no one-size-fits-all answer. The decision to continue, adjust, or discontinue SSRIs during pregnancy requires an honest, detailed conversation between you and your healthcare provider that weighs both the specific risks associated with your particular medication and the well-documented risks of untreated mental health conditions. The goal is not to fear SSRIs or to dismiss them as completely safe, but to make an informed choice based on your individual circumstances, your medical history, and the latest evidence.